Company
Sperotherapeutics
Developing Novel Medicines for Immune-Mediated Diseases
Also known as Spero Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Spero Therapeutics is a clinical-stage biopharmaceutical company advancing innovative medicines for immune-mediated diseases, beginning with SP001, a third-generation anti-CD40L antibody in development for IgG4-related disease.
Funding snapshot
- Total raised
- $92.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $9M2022-11-07
Funding rounds
- Round, 2022
- $9M2022-11-07, SEC form D sold, 1 investor
- Round, 2021
- $40M2021-06-30, SEC form D sold, 1 investor
- Round, 2017
- $43.2M2017-03-07, SEC form D sold, 11 investors
Products
- Other
- SP001
- Other
- Utebzi
Loading relationship preview